Toronto, Canada – Renata PLC has officially entered the Canadian pharmaceutical market with the launch of its first product: Desogestrel/Ethinylestradiol (0.15mg/0.03mg) oral contraceptive tablets.

The product, a fixed-dose combination of Desogestrel (a progestin) and Ethinylestradiol (an estrogen), is being introduced under the brand names Miley 21 and Miley 28. It will be commercialised through a strategic partnership with Ambicare Pharmaceuticals Inc., a Canadian company known for its portfolio of high-quality, niche generic products across multiple therapeutic areas.

The tablets are manufactured at Renata’s Health Canada-approved potent product facility, ensuring compliance with stringent quality and regulatory standards.

Renata also markets the same formulation in Bangladesh under the brand name Desolon.

This marks a significant milestone for Renata as it expands into North America, with plans to grow its product portfolio in the Canadian market.